<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21798">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037412</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0764</org_study_id>
    <nct_id>NCT02037412</nct_id>
  </id_info>
  <brief_title>Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that ticagrelor may enhance endothelial healing after DES
      implantation by increasing adenosine concentrations by the inhibition of adenosine uptake
      into erythrocytes, compared to clopidogrel. Thus, the investigators will evaluate the extent
      of endothelialization (stent strut coverage) and neointimal hyperplasia (neointimal
      thickness) 3 months after DES implantation by optical coherence tomography (OCT)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stent re-endothelialization</measure>
    <time_frame>Three months after stent implantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of stent coverage measured by OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neointimal hyperplasia</measure>
    <time_frame>Three months after stent implantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neointimal thickness measured by OCT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Patients Who Are Hospitalized and Expected to Undergo PCI for Acute Coronary Syndrome, Including Acute Myocardial Infarction and Unstable Angina.</condition>
  <arm_group>
    <arm_group_label>Ticagrelor Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months</description>
    <arm_group_label>Ticagrelor Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months</description>
    <arm_group_label>Clopidogrel Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥ 20 years old

          -  Patients who are hospitalized and expected to undergo PCI for acute coronary
             syndrome, including acute myocardial infarction and unstable angina.

        Exclusion Criteria:

          -  Age &gt; 80 years

          -  Cardiogenic shock or unstable patients

          -  Increased risk of bleeding, anemia, thrombocytopenia

          -  A need for oral anticoagulation therapy

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myeong-Ki Hong, MD</last_name>
    <phone>82-2-2228-8460</phone>
    <email>mkhong61@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myeong-Ki Hong, MD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>mkhong61@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Patil SB, Jackman LE, Francis SE, Judge HM, Nylander S, Storey RF. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2385-91. doi: 10.1161/ATVBAHA.110.210732. Epub 2010 Nov 11.</citation>
    <PMID>21071697</PMID>
  </reference>
  <reference>
    <citation>Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, Park SM, Paik SI, Ko YG, Hong MK, Jang Y, Chung N. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol. 2011 Feb 3;146(3):341-6. doi: 10.1016/j.ijcard.2009.07.012. Epub 2009 Aug 25.</citation>
    <PMID>19709765</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>strut coverage</keyword>
  <keyword>DES</keyword>
  <keyword>ACS</keyword>
  <keyword>OCT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
